1 not yet recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Post-COVID-19 Condition (PCC or Long COVID): new trials by email Literature Review of Post-COVID-19 Condition (PCC or Long COVID) trials Research Report on Post-COVID-19 Condition (PCC or Long COVID)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Post-acute Infectious Syndrome - Aripiprazole Symptom Evaluation (PAIS-AriSE) Aripiprazole (low-dose, 1mg), Placebo - Post-acute Infectious Syndrome (PAIS), Post-COVID-19 Condition (PCC or Long COVID) | Phase 2 | Not yet recruiting | Christiana Franke | 138 | 2026-10-01 | 2026-07-20 |
Cognition Disorders (1) · Fatigue (1) · Hemophilia B (1) · Post-Acute COVID-19 Syndrome (1)
Blood Coagulation Disorders (1) · Blood Coagulation Disorders, Inherited (1) · COVID-19 (1) · Chronic Disease (1) · Coagulation Protein Disorders (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Disease Attributes (1) · Genetic Diseases, Inborn (1) · Genetic Diseases, X-Linked (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemorrhagic Disorders (1) · Infections (1)
Aripiprazole (1)
Germany (1)